DK30092D0 - Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler - Google Patents

Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler

Info

Publication number
DK30092D0
DK30092D0 DK92300A DK30092A DK30092D0 DK 30092 D0 DK30092 D0 DK 30092D0 DK 92300 A DK92300 A DK 92300A DK 30092 A DK30092 A DK 30092A DK 30092 D0 DK30092 D0 DK 30092D0
Authority
DK
Denmark
Prior art keywords
patient
lollipop
methods
aedosis
lipofile
Prior art date
Application number
DK92300A
Other languages
English (en)
Other versions
DK175773B1 (da
DK30092A (da
Inventor
Theodore H Stanley
Brian Hague
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of DK30092D0 publication Critical patent/DK30092D0/da
Publication of DK30092A publication Critical patent/DK30092A/da
Application granted granted Critical
Publication of DK175773B1 publication Critical patent/DK175773B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK199200300A 1989-09-05 1992-03-05 Fremgangsmåde og midler til ikke-invasiv "dosis-til-virkning" administration af lipofile lægemidler DK175773B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1989/003801 WO1991003233A1 (en) 1989-09-05 1989-09-05 Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
US8903801 1989-09-05

Publications (3)

Publication Number Publication Date
DK30092D0 true DK30092D0 (da) 1992-03-05
DK30092A DK30092A (da) 1992-05-05
DK175773B1 DK175773B1 (da) 2005-02-14

Family

ID=22215208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199200300A DK175773B1 (da) 1989-09-05 1992-03-05 Fremgangsmåde og midler til ikke-invasiv "dosis-til-virkning" administration af lipofile lægemidler

Country Status (8)

Country Link
EP (1) EP0493380B1 (da)
JP (1) JP2758985B2 (da)
AT (1) ATE159658T1 (da)
AU (2) AU645966B2 (da)
DE (1) DE68928415T2 (da)
DK (1) DK175773B1 (da)
NO (2) NO920854L (da)
WO (1) WO1991003233A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (da) * 1977-08-05 1981-07-15 Battelle Memorial Institute
EP0745380B1 (en) * 1995-05-11 2005-08-03 University Of Utah Research Foundation Tobacco substitute
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
US7776831B2 (en) * 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20160022643A1 (en) * 2014-07-22 2016-01-28 Professional Compounding Centers Of America Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men
US10525099B2 (en) 2014-10-01 2020-01-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
HUE051974T2 (hu) 2014-10-01 2021-04-28 Oxytone Bioscience B V Szájban szétesõ, szülést szabályozó ágenst tartalmazó, szilárd halmazállapotú gyógyászati dózisegység
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2208120A (en) * 1938-03-02 1940-07-16 William B Coleman Pharmaceutical preparation and method of making same
US3943928A (en) * 1974-09-25 1976-03-16 Lariccia Anthony H Eliminating the safety hazard in oral dissolution of a solid
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics

Also Published As

Publication number Publication date
NO920854L (no) 1992-04-27
AU6069794A (en) 1994-06-23
EP0493380A1 (en) 1992-07-08
WO1991003233A1 (en) 1991-03-21
NO920855D0 (no) 1992-03-04
DK175773B1 (da) 2005-02-14
DE68928415D1 (de) 1997-12-04
EP0493380B1 (en) 1997-10-29
AU645966B2 (en) 1994-02-03
JP2758985B2 (ja) 1998-05-28
ATE159658T1 (de) 1997-11-15
DE68928415T2 (de) 1998-02-26
EP0493380A4 (en) 1992-10-07
NO920855L (no) 1992-04-10
DK30092A (da) 1992-05-05
NO920854D0 (no) 1992-03-04
AU5035290A (en) 1991-04-08
JPH05501854A (ja) 1993-04-08

Similar Documents

Publication Publication Date Title
Bowles et al. Evaluation of new gingival retraction agents
Kennedy et al. Intravenous regional analgesia: an appraisal
DE69003392D1 (de) Dosisform zur oralen verabreichung des hypoglykämischen glipizids.
ATE113203T1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
UY26425A1 (es) Formulación y método antidiabético
NL990012I2 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
DE69002718T2 (de) Medikamente.
DK30092D0 (da) Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
Bloom et al. Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: A double-blind cross-over study with methyldopa.
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
Snir et al. Central venous stasis retinopathy following the use of tranexamic acid
Sugai et al. Sequential changes in the fade of tetanic tension after the administration of tubocurarine in anaesthetized man
Clement Effect of indoramin on finger blood flow in vasospastic patients
EP0397211A3 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
Reynolds et al. Circulatory versus respiratory deaths from pentothal sodium
CN2233753Y (zh) 护心袋
RU94018748A (ru) Лекарственный сбор для лечения больных с нарушениями сердечного ритма
Samuels et al. Regional anesthesia for the emergency department physician
Wilbert Drug Intoxication: An Economic Waste and a Menace to Public Health
RU94019564A (ru) Способ лечения желудочно-кишечных заболеваний
CN1174914A (zh) 防治呼吸道疾病的药物纸巾
Woods Sedation for dental treatment of infants. II. Clinical procedure

Legal Events

Date Code Title Description
PUP Patent expired